Higher immunogenicity is associated with higher therapeutic efficacy of TGF-β inhibition, as was observed in a study where TGF-β inhibition using kinase inhibitor galunisertib resulted in stronger CD8+ T-cell dependent control of tumor growth of immunogenic 4T1-luciferase breast tumors, compared with poorly immunogenic 4T1 parental tumors (40). This evidence concerns the gene TGFB1 and breast neoplasm.